These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25687792)

  • 1. Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites.
    Juhlin K; Karimi G; Andér M; Camilli S; Dheda M; Har TS; Isahak R; Lee SJ; Vaughan S; Caduff P; Norén GN
    Drug Saf; 2015 Apr; 38(4):373-82. PubMed ID: 25687792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of cluster adverse drug events in the spontaneous reporting system of China using a disproportionality filter algorithm.
    Wang M; Ye X; Ruan Y; Xu J; Guo X; Dong D; Feng H; He J
    J Clin Pharm Ther; 2019 Dec; 44(6):952-957. PubMed ID: 31407823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues.
    Bergvall T; Norén GN; Lindquist M
    Drug Saf; 2014 Jan; 37(1):65-77. PubMed ID: 24343765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.
    Star K; Norén GN; Nordin K; Edwards IR
    Drug Saf; 2011 May; 34(5):415-28. PubMed ID: 21513364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase
    Chandler RE; Juhlin K; Fransson J; Caster O; Edwards IR; Norén GN
    Drug Saf; 2017 Jan; 40(1):81-90. PubMed ID: 27638661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre.
    Star K; Sandberg L; Bergvall T; Choonara I; Caduff-Janosa P; Edwards IR
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):680-689. PubMed ID: 30767342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bad medicine. Monitoring programs target substandard drugs.
    Grens K
    Mod Healthc; 2013 May; 43(20):30-1. PubMed ID: 23947275
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
    Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN
    Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy.
    Juhlin K; Ye X; Star K; Norén GN
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1119-29. PubMed ID: 23832706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substandard medicines in resource-poor settings: a problem that can no longer be ignored.
    Caudron JM; Ford N; Henkens M; Macé C; Kiddle-Monroe R; Pinel J
    Trop Med Int Health; 2008 Aug; 13(8):1062-72. PubMed ID: 18631318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.
    Strandell J; Caster O; Bate A; Norén N; Edwards IR
    Drug Saf; 2011 Mar; 34(3):253-66. PubMed ID: 21332249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of probabilistic method to detect duplicate individual case safety reports.
    Tregunno PM; Fink DB; Fernandez-Fernandez C; Lázaro-Bengoa E; Norén GN
    Drug Saf; 2014 Apr; 37(4):249-58. PubMed ID: 24627310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Quality of medicines in least developed countries].
    Videau JY
    Med Trop (Mars); 2006 Dec; 66(6):533-7. PubMed ID: 17286015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substandard drugs: a potential crisis for public health.
    Johnston A; Holt DW
    Br J Clin Pharmacol; 2014 Aug; 78(2):218-43. PubMed ID: 24286459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: a case series analysis.
    Star K; Iessa N; Almandil NB; Wilton L; Curran S; Edwards IR; Wong IC
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):440-51. PubMed ID: 23234587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.